A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease

Sponsor
Incyte

Protocol Number
INCB 18424-271

To Learn More Call
201-510-0910